Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/s0041-1345(98)01543-7 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Solid Self-Microemulsifying Drug Delivery System for Improved Oral Bioavailability of Relugolix: Preparation and Evaluation.
Int J Nanomedicine
January 2025
School of Pharmacy, Jiangxi Medical College, Nanchang University, Nanchang, 330006, People's Republic of China.
Purpose: To improve the oral absorption of relugolix (RLGL), which has low oral bioavailability due to its low solubility and being a substrate of P-glycoprotein (P-gp). A solid self-microemulsifying drug delivery system of relugolix (RLGL-S-SMEDDS) was prepared and evaluated in vitro and in vivo.
Methods: The composition of the solid self-microemulsifying drug delivery system (S-SMEDDS) was selected by solubility study and pseudo-ternary phase diagram, and further optimized by Design-Expert optimization design.
Risk factor analysis and prediction of multi-organ metastasis in hepatic alveolar echinococcosis.
Saudi J Gastroenterol
January 2025
Department of General Surgery, Qinghai Provincial People's Hospital, Xining, Qinghai Province, China.
Background: Patients with multiple organ metastases from hepatic alveolar echinococcosis have a high mortality rate. However, predictors of multi-organ metastasis have not been identified. We aimed to develop a nomogram that predicts multi-organ metastasis in patients with hepatic alveolar echinococcosis.
View Article and Find Full Text PDFEfficacy and Safety of Dapagliflozin Compared to Pioglitazone in Diabetic and Non-Diabetic Patients with Non-alcoholic Steatohepatitis: A Randomized Clinical Trial.
Clin Res Hepatol Gastroenterol
January 2025
Department of Clinical Pharmacy, Faculty of Pharmacy, Cairo University, Egypt. Electronic address:
Background: Non-alcoholic steatohepatitis (NASH) is a serious end-stage spectrum of non-alcoholic fatty liver disease (NAFLD) with associated high risk of hepatic and extrahepatic complications. Several studies showed the significant beneficial effect of dapagliflozin on body composition, hepatic and metabolic parameters on NAFLD/NASH patients. The study aimed to investigate the efficacy and safety of dapagliflozin in both diabetic and non-diabetic biopsy-proven NASH patients; compared to pioglitazone.
View Article and Find Full Text PDFNon-Target Hemangioma Size Reduction After Bleomycin-Lipiodol Embolization of Primary Hepatic Hemangioma.
J Vasc Interv Radiol
January 2025
Inonu University, Faculty of Medicine, Department of Biostatistics and Medical Informatics, Malatya, Türkiye.
Purpose: To evaluate changes in non-target hepatic hemangiomas, which are neither subjected to embolization nor targeted for treatment, following selective bleomycin-lipiodol transarterial chemoembolization (TACE) of a giant hepatic hemangioma.
Materials And Methods: This single-center retrospective study included 24 patients with non-target hepatic hemangiomas distinct from primary giant hemangiomas treated with selective bleomycin-lipiodol TACE between 2009 and 2022. The size and volume of the lesions were assessed using computed tomography scans obtained before treatment, and at 6, 12 and 24 months.
Hemoadhican Fiber Composite with Carbon Dots for Treating Severe Hemorrhage and Infected Wounds.
ACS Appl Mater Interfaces
January 2025
Center for Molecular Metabolism, Nanjing University of Science & Technology, Nanjing, Jiangsu 210094, China.
Uncontrolled bleeding and infection following trauma continue to pose significant clinical challenges. This study employs hemoadhican (HD) polysaccharide, known for its superior hemostatic properties, as the foundational material to synthesize antibacterial carbon dots (H-CDs) through a hydrothermal method at various temperatures. The H-CDs exhibiting optimal antimicrobial properties were identified via in vitro antimicrobial characterization.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!